Next 10 |
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
2024-04-01 09:14:30 ET More on biolinerx Seeking Alpha’s Quant Rating on biolinerx Financial information for biolinerx Read the full article on Seeking Alpha For further details see: BioLineRx to raise $6M through a direct offering
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...
2024-03-26 11:53:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ: BLRX ) just reported results for the fourth quarter of 2023. BioLine Rx reported earnings per share of -15 cents. This was above the analyst estimate f...
2024-03-26 11:38:10 ET BioLineRx Ltd. (BLRX) Q4 2023 Earnings Conference Call March 26, 2024 08:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO ...
2024-03-26 08:15:52 ET More on Pre-market losers & stocks. Canoo: Positive News Isn't Enough Canoo: Avoid After Reverse Stock Split Canoo: There Is A Glimpse Of Hope But Hold Canoo completes acquisition of manufacturing assets from Arrival Canoo's...
2024-03-26 07:02:31 ET More on biolinerx Seeking Alpha’s Quant Rating on biolinerx Historical earnings data for biolinerx Financial information for biolinerx Read the full article on Seeking Alpha For further details see: BioLineRx GAAP EPS...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at t...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...